Latest White Paper
- |
- 2025
- |
- 2025-06-16
New Product Alert – Ruxolitinib Phosphate
Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK inhibitors). It is an inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2.This inhibition disrupts cytokine and growth factor signalling pathw... [Más ]
Year 2025
- |
- 2025
- |
- 2025-06-16
New Product Alert – Ruxolitinib Phosphate
Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK inhibitors). It is an inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2.This inhibition disrupts cytokine and growth factor signalling pathw... [Más ]
- |
- 2025
- |
- 2025-05-05
Product Alert – Mavacamten
CAS No. 1642288-47-8Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridg... [Más ]
- |
- 2025
- |
- 2025-04-03
Product Alert – Ruxolitinib Phosphate
Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK inhibitors). It is an inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2.This inhibition disrupts cytokine and growth factor signalling pathw... [Más ]
Year 2024
- |
- 2024
- |
- 2024-12-18
Tech Sheet On Nilotinib Hydrochloride
Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, Nilotinib inhibited BCR-ABL-mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ chronic mye... [Más ]
- |
- 2024
- |
- 2024-10-18
Tech Sheet – Mirabegron API
CAS no. 223673-61-8Mirabegron is a ß-3 adrenergic receptor agonist and a widely prescribed oral drug for treating overactive bladder (OAB). The drug improves symptoms associated with OAB, such as urinary urgency or urgency incontinence.Mirabegron was approved under the trade names Myrbetriq (US, 201... [Más ]
- |
- 2024
- |
- 2024-09-25
Tech sheet – Apremilast
Dr. Reddy's API Offerings*:Dr. Reddy's is among the earliest generic API manufacturers globally for Apremilast API and filed the USDMF in September 2016 (Form-B) and June 2017 (Amorphous). Besides this, we have DMF filings in Canada and Brazil.Offers the same form as the innovator drug, facilitating... [Más ]
- |
- 2024
- |
- 2024-05-31
Product Alert - Relugolix API
CAS No: 737789-87-6As an early mover in API development, we are committed to regulatory compliance, have DMFs filling in the US and Brazil, and plan to file the DMFs in significant markets. Our API is available in an anhydrous crystalline form (the innovator form), which can be provided in customize... [Más ]
- |
- 2024
- |
- 2024-05-31
Tech Sheet on Enzalutamide Premix
Chemical Name:4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N- methylbenzamide.Dr. Reddy's API Offerings*:Innovator has filed an Enzalutamide premix amorphous form manufactured through spray drying, which uses API and HPMCAS as excipients. We offer a... [Más ]
- |
- 2024
- |
- 2024-05-31
Product Alert – Mirogabalin Besylate
Dr. Reddy's Offerings*:Planning USDMF by January 2025Offers crystalline Form-1Non-GMP API and COA are available.Quality Assurance through cGMP API ManufacturingManufacturing facilities have successfully undergone inspections by international regulatory authorities.Partnerships with reliable key star... [Más ]
- |
- 2024
- |
- 2024-04-22
Product Alert – Vonoprazan Fumarate
Dr. Reddy's Offerings:USDMF filed in februray 2024Offers crystalline innovator form.Our API adheres to ICH M7 guidelines for genotoxic impurity (GTI) profiles, and we are actively evaluating strategies for nitrosamine impurities. We have also employed a robust process to achieve the consistent polym... [Más ]
- |
- 2024
- |
- 2024-02-21
Tech Sheet - Cabozantinib (S)-malate API
Cabozantinib S-malate is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.Dr. Reddy's API Offering*We offer Cabozantinib S-malate – Crystalline form N2 (Innovator form).Cabozantinib HCl is an alternate salt providing 505(b)(2) opp... [Más ]
Year 2023
- |
- 2023
- |
- 2023-12-07
Product Alert – Deucravacitinib API
CAS no. 1609392-27-9Dr. Reddy's API OfferingWe are targeting crystalline Form and working on other amorphous solid dispersions (ASDs) as well. Our API adheres to ICH M7 guidelines for genotoxic impurity (GTI) profiles, and we are actively evaluating strategies for nitrosamine impurities. We have als... [Más ]
- |
- 2023
- |
- 2023-12-04
Substantially Pure Carfilzomib Amorphous for Generic Launch
Kyprolis (carfilzomib) is a proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic... [Más ]
- |
- 2023
- |
- 2023-11-06
Product Alert – Mavacamten API
CAS no. 1642288-47-8Mavacamten (Camzyos®) is the pioneering and singularly authorised cardiac myosin inhibitor designed to address hypertrophic cardiomyopathy (HCM) at its root cause. This unique compound acts as an allosteric and reversible inhibitor with a specific focus on cardiac myosin, allowin... [Más ]
- |
- 2023
- |
- 2023-07-21
White Paper on Sugammadex API
Sugammadex is a medication used to reverse the effects of certain muscle-relaxing drugs (rocuronium and vecuronium) during anaesthesia. It works by forming a complex with these drugs, neutralizing their effects, and restoring muscle function, allowing for a rapid reversal of muscle relaxation. Sugam... [Más ]
- |
- 2023
- |
- 2023-07-21
Tech Sheet on Pregabalin API
Pregabalin's precise mechanism of action is not fully understood, but studies suggest that it binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system. This binding modulates the release of excitatory neurotransmitters and prevents the trafficking of the alph... [Más ]
- |
- 2023
- |
- 2023-03-20
Product Alert – Niraparib API
Niraparib binds to the PARP enzyme and prevents it from repairing single-strand breaks in DNA. This causes the cancer cell's DNA to become more damaged, leading to cell death. Since cancer cells often have more DNA damage than healthy cells, they are more sensitive to the effects of PARP inhibitors ... [Más ]
- |
- 2023
- |
- 2023-03-13
Product Alert – Tucatinib API
Tucatinib is a small molecule tyrosine kinase inhibitor that selectively targets human epidermal growth factor receptor 2 (HER2). HER2 is a transmembrane receptor that is overexpressed in some types of cancer, including breast cancer.Tucatinib binds to the intracellular domain of HER2, which blocks ... [Más ]
- |
- 2023
- |
- 2023-03-06
Product Alert – Pazopanib API
Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kin... [Más ]
- |
- 2023
- |
- 2023-01-20
Tech Sheet on Midostaurin API
Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that Midostaurin or its major human active metabolites CGP62221 and CGP52421 inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT (wild type ... [Más ]
- |
- 2023
- |
- 2023-01-09
Tech Sheet on Tofacitinib Citrate
Tofacitinib Citrate (Xeljanz) is an oral, small molecule drug used to treat adults with moderate to severe active rheumatoid arthritis (RA), active psoriatic arthritis, and moderate to severe ulcerative colitis. Tofacitinib works by blocking the body’s production of enzymes called Janus kinases (JAK... [Más ]
Year 2022
- |
- 2022
- |
- 2024-08-04
Addressing the presence of mutagenic Azido impurities in Sartan APIs
In continuation to our efforts to understand the Azido impurities, we are evaluating the possibility of formation of two additional Azido impurities - Chloro methyl azido impurity and 4-Chloro azido methyl tetrazole impurity in Losartan potassium. Based on detailed synthetic landscape, it is found t... [Más ]
- |
- 2022
- |
- 2022-11-04
Tech Sheet on Dutasteride
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT). DHT is the androgen primarily responsible for the prostate gland's initial development and subsequent enlargement. Testosterone is converted to DHT by the enzyme 5-alpha-reductase, which exists as 2- isoforms, type 1 a... [Más ]
- |
- 2022
- |
- 2022-10-14
Tech Sheet on Linagliptin
Linagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of ... [Más ]
- |
- 2022
- |
- 2022-10-12
Tech Sheet on Voriconazole
Voriconazole (Vfend®) is an azole antifungal indicated for invasive aspergillosis candidemia (non- neutropenic) and disseminated candidiasis in skin, abdomen, kidney, bladder wall, and wounds, and esophageal candidiasis. Furthermore, it is used to treat serious infections caused by scedosporium apio... [Más ]
- |
- 2022
- |
- 2022-08-03
Co-Crystal and Customized Particle Size for Early Launch Opportunity of Siponimod API
Siponimod is an oral, second-generation sphingosine-1-phosphate (S1P) receptor modulator. S1P receptor modulators can inhibit the egress and recirculation of lymphocytes from lymph nodes, a therapeutic strategy for treating certain autoimmune diseases.Siponimod is the first and only treatment for pa... [Más ]
- |
- 2022
- |
- 2022-07-29
New Product Alert – Lumateperone Tosylate API
Lumateperone is a serotonin 5HT2A receptor antagonist, a dopamine receptor phosphoprotein modulator (DPPM), and a serotonin transporter (SERT) inhibitor. Unlike existing schizophrenia treatments, Lumateperone is a first-in-class molecule that provides selective and simultaneous modulation of seroton... [Más ]
- |
- 2022
- |
- 2022-06-15
Tech sheet: Dr. Reddy's Bempedoic Acid API Offerings
Bempedoic acid (Brand: Nexletol, Innovator: Esperion) is an essentially new, oral treatment option approved for patients needing further LDL-C lowering beyond maximally tolerated statin therapy. Bempedoic acid is the first oral, once-daily, non-statin LDL-C lowering medicine approved since 2002 for ... [Más ]
- |
- 2022
- |
- 2022-04-04
Tech sheet: Dr. Reddy's Olaparib API Offerings
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostases, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib is indicated:As monotherapy in patients with deleterious or... [Más ]
- |
- 2022
- |
- 2022-03-30
Tech sheet: Dr. Reddy's Enzalutamide API Offerings
Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signalling pathway. Enzalutamide has been shown to inhibit androgen binding to androgen receptors competitively and consequently inhibits nuclear translocation of androgen receptors and their interac... [Más ]
- |
- 2022
- |
- 2022-02-22
Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings
Eribulin Mesylate (Halaven®) is a microtubule inhibitor indicated to treat patients with:Metastatic breast cancer who have previously received at least two chemotherapeutic regimens to treat metastatic disease.Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing ... [Más ]
- |
- 2022
- |
- 2022-02-09
Tech Sheet – Dr. Reddy’s Fexofenadine API offerings
Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective peripheral H1-receptor antagonist activity. Fexofenadine Hydrochloride is indicated for:The relief of symptoms associated with seasonal allergic rhinitis in patients ≥ 2 years of age.To treat u... [Más ]
- |
- 2022
- |
- 2022-02-04
Tech Sheet - Dr. Reddy’s Azacitidine API offerings
Azacitidine is a nucleoside metabolic inhibitor indicated to continue treating adult patients with acute myeloid leukemia. In addition, it is indicated for use in adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count r... [Más ]
- |
- 2022
- |
- 2022-02-04
Tech Sheet - Dr. Reddy’s Ramipril API offerings
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor indicated for treating hypertension to lower blood pressure. ACE inhibitors inhibit the angiotensin-converting enzyme (ACE) actions, thereby reducing the production of angiotensin II and decreasing the breakdown of bradykinin. The decrease... [Más ]
Year 2021
- |
- 2021
- |
- 2021-12-17
Tech Sheet - Dr. Reddy’s Gemcitabine API offerings
Gemcitabine Hydrochloride is an analog of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di-and triphosphate (dFdCDP and dFdCTP)dFdCDP - Inhibits ribonucleotide reductase, decreasing t... [Más ]
- |
- 2021
- |
- 2021-12-02
Tech Sheet: Dr. Reddy’s Abiraterone Acetate API offerings
Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 selectively and irreversibly via a covalent binding mechanism. Abiraterone is a CYP17 inhibitor indicated in combination with prednisolone to treat patients with metasta... [Más ]
- |
- 2021
- |
- 2021-10-08
Formulación de Remdesivir desarrollado en Dr. Reddy’s conforme ala licencia de Gilead:
Remdesivir es el primer tratamiento aprobado por la FDA (Administración de Medicamentos y Alimentos) de Estados Unidos para el tratamiento de la COVID-19 en pacientes adultos y pediátricos (de 12 años de edad o mayores y que pesen, al menos, 40 kg) que requieran hospitalización. Es un inhibidor dela... [Más ]
- |
- 2021
- |
- 2021-08-17
Libro blanco: 2 DG de Dr. Reddy’s - Un tratamiento prometedor para pacientes hospitalizados con COVID-19.
La 2-Desoxi-D-Glucosa (2-DG) es un fármaco antiviral y antiinflamatorio desarrollado por el Instituto de Medicina Nuclear y Ciencias Afines (INMAS) de la Organización de Investigación y Desarrollo para la Defensa (DRDO). Dr. Reddy’s colaboró con DRDO para realizar ensayos clínicos con la 2 DG en pac... [Más ]
- |
- 2021
- |
- 2021-08-17
Techsheet: Dr.Reddy's Lenvatinib API offerings
Lenvima is an oral tyrosine kinase inhibitor approved in multiple indications, including differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.We offer two polymorphic forms:1) Lenvatinib Mesylate MIBK solvate2) Lenvatinib Mesylate Form-C.A MIBK sol... [Más ]
- |
- 2021
- |
- 2021-06-18
ROXADUSTAT – una estrategia de desarrollo multidisciplinario
En este libro blanco, revelamos cómo distintas estrategias para el desarrollo de Roxadustat resultaron en un llenadoexitoso del DMF de Estados Unidos en marzo de 2020 para ayudar a que nuestros socios internacionalesbrinden a sus pacientes un acceso inmediato a los tratamientos.Roxadustat es una mol... [Más ]
- |
- 2021
- |
- 2021-05-19
Dr.Reddy's Apremilast API and finished formulation offerings.
Dr. Reddy's is one of the leading API pharma companies supplying Apremilast API globally, and has led the USDMF filing in September 2016 (Form-B) and June 2017 (Amorphous).Apremilast, is an anti-inflammatory agent modulating a wide range of inflammatory mediators in psoriasis and psoriatic arthritis... [Más ]
- |
- 2021
- |
- 2021-05-03
Dr. Reddy’s Fosaprepitant API offerings
Fosaprepitant is indicated for preventing acute and delayed nausea and vomiting associated with moderately or highly emetogenic chemotherapy combined with other antiemetic agents. The US FDA and EMA approved fosaprepitant in 2008, and the PMDA in 2011. As of December 2020, this corresponds to an API... [Más ]
- |
- 2021
- |
- 2021-04-15
IFA de Apixaban – grageas y formas farmacéuticas terminadas listas para comprimir.
Dr. Reddy’s se encuentra entre los fabricantes genéricos de IFA más jóvenes a nivel mundial por losIFA de Apixaban y presentó el DMF de Estados Unidos en septiembre de 2015. Nuestros clientes tienen acceso API de alta calidad en tamaños de partículas personalizados para agilizar el desarrollo de la ... [Más ]
- |
- 2021
- |
- 2021-04-06
Los IFA de Apalutamide – una oportunidadatractiva de NCE-1para las compañías farmacéuticas genéricas.
El cáncer de próstata representa un 7.3% de todos los casos incidentes de cáncer a nivel mundial, de acuerdo con estadísticas publicadas en 2020 por Globocan.La prevalencia a los 5 años de cáncer de próstata se estima en cinco millones alrededor del mundo, lo que lo convierte en el segundo cáncer má... [Más ]
- |
- 2021
- |
- 2021-04-06
Formulaciones Coloidales de Hierro Complejas – Entendimiento y Desarrollo del Proceso
El libro blanco describe los desafíos incluidos en el desarrollo de carbohidratos complejos de hierro,, incluidos los parámetros requeridos para demostrar la equivalencia fisicoquímica, y resume nuestra experiencia para tratarlos. Los carbohidratos complejos de hierro son un híbrido de molécula... [Más ]
- |
- 2021
- |
- 2021-02-09
Rivaroxaban de Dr. Reddy’s: Canasta llena de ofertas de IFA y Formulaciones terminadas.
Dr. Reddy’s se encuentra entre los fabricantes de API globalmente para API de rivaroxabán y presentó el DMF de Estados Unidos en marzo de 2014. Dr. Reddy’s El proceso de incluye transformaciones de químicos selectivas y eficaces que ofrecen una ventaja distintiva para la calidad y fabricación.E... [Más ]
- |
- 2021
- |
- 2021-01-22
Oferta de IFA de Mirabegron de Dr. Reddy's en fórmulas alfa y amorfo.
Lea nuestra ficha técnica sobre API de Mirabegrón para tener una idea de nuestro enfoque sintético progresivo con caracterización analítica eficaz que resulta en un IFA altamente puro. Dr. Reddy’s se encuentra entre los Fabricantes de API a nivel mundial y presentó el DMF de Estados Unidos para... [Más ]
- |
- 2021
- |
- 2021-01-13
Palbociclib – cómo un enfoque desarrollista de un proceso innovador provee ventajas de IP.
Este libro blanco describe cómo el enfoque holístico de desarrollo de Dr. Reddy’s puede ayudar a nuestros socios de IFA alrededor del mundo para brindar a los pacientes el acceso inmediato a la alternativa genérica dePalbocicilb mientras se ganan o mantienen ventajas competitivas.Nuestro equipo... [Más ]
Year 2020
- |
- 2020
- |
- 2020-11-25
La oferta de IFA de Elagolix de Dr. Reddy’s promueve un Enfoque de total Calidad por Diseño.
La ficha técnica del producto en nuestro API de elagolix describe el Enfoque de Calidad por Diseño (QbD) aceptado por el equipo de R&D (Investigación y Desarrollo) de Dr. Reddy’s para el desarrollar el producto. En consecuencia, Dr. Reddy’s es uno de los primeros y pocos fabricantes API genérica... [Más ]
- |
- 2020
- |
- 2020-07-20
Sacubitril/Valsartan (LCZ696) – Bringing yet another advantage through innovative API offerings
Our team of process and analytical experts draw on their integrated understanding in both the development and manufacturing of the API and the formulation. This is of particular importance when it comes to the characterization of a molecular complex which is critical for a successful API and formula... [Más ]
- |
- 2020
- |
- 2020-07-10
Los expertos en Química de Flujo de Dr. Reddy’s comparten sus perspectivas en el panel de debate de la revista Chemistry Today.
Junio de 2020Los expertos en Química de Flujo de Dr. Reddy’s, Srividya Ramakrishnan y Rakeshwar Bandichhor, participaron recientemente en el panel de debate de la revista Chemistry Today, donde compartieron sus perspectivas acerca de la tecnología de flujo y la posibilidad de convertirse en una alte... [Más ]
- |
- 2020
- |
- 2020-05-20
Un estudio detallado de cómo Dr. Reddy’s cumplió con los rigurosos requisitos regulatorios de las impurezas genotóxicas en la Ranolazina.
No hace mucho las impurezas genotóxicas (GTI) desafiaron a la industria farmacéutica con su presencia a un nivel de partes por millón (ppm) en medicamentos, en especial, en moléculas de dosificación alta como la Ranolazine, , para la cual se prescribe una dosis máxima diaria (MDD) de 2000 mg.En este... [Más ]
- |
- 2020
- |
- 2020-05-07
API de Famotidina y Nizatidina:NDMA (N-nitrosodimetilamina) controlada, distribución de partícula personalizada, seguridad en cadena de suministro
Durante más de dos décadas, Dr. Reddy’s ha sido reconocido como uno de los mayores fabricantes de API del antagonista de receptores H2, tales como la Famotidina y la Nizatidina. Nuestros IFA de Tidina son utilizados por compañías de formulaciones a lo largo de Europa, Estados Unidos, Japón, Medio Or... [Más ]
Year 2019
- |
- 2019
- |
- 2019-10-17
Cumplimiento de los Nuevos Requisitos Regulatorios en la Producción de IFA de Sartán.
fabricante de APIs Ahora se requiere que el verifique sus procesos de fabricación y compruebe la ausencia de impurezas de nitrosamina. Este libro blanco describe las regulaciones y un estudio de caso sobre cómo los IFA de Dr. Reddy’s Sartan de API’s (such as Valsartan) ya cumple con los futuros requ... [Más ]
Descargo de responsabilidad
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.